Document is current
Any future updates will be listed below
-
Authors
Hammond, Emily E.
McDonald, Charles S.
Vestbo, Jørgen
Denning, David W. http://orcid.org/0000-0001-5626-2251
-
Funding
Funding for this research was provided by:
Manchester Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 15 July 2020
Accepted: 5 August 2020
First Online: 11 September 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: EEH and CMcD have no competing interests. JV reports personal fees from GlaxoSmithKline, personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, grants from Boehringer-Ingelheim, outside the submitted work. DWD reports that he and family hold Founder shares in F2G Ltd., a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Roivant, Biosergen, and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.
